The healthcare crew at BIS Analysis, just lately, concluded an in depth webinar on ‘Liquid Biopsy: An Rising Frontier in Early Multicancer Detection’. The webinar was hosted by principal guide, Nitish Kumar, and senior analysis analyst, Riya Gupta. The visitor on this webinar was Mr. Azeet Narayan, principal scientist at Sema4.
The session was filled with business insights in addition to deep advertising and marketing intelligence round liquid biopsy approach and its influence on multicancer detection course of. Some very essential questions have been raised in the course of the session by the attendees, which have been duly answered by the panel of audio system.
Right here’s an excerpt from the QnA that passed off in the course of the webinar:
a) How do you see the marketplace for end-to-end options vs. modular method equivalent to separate suppliers for kits and separate suppliers for evaluation software program?
In response to BIS Analysis evaluation, the liquid biopsy market may be divided in keeping with totally different choices into testing companies, kits, platform and different consumables. Out of those testing companies are anticipated to dominate the market with a 40-50% market share, adopted by platform with a 20-30% market share in 2021. Kits had a market share between 5-15% and Different consumables 15-25% in 2021.
b) Why do you suppose extracellular vesicles (EVs) will dominate the liquid biopsy market within the coming future, is it when it comes to medical facets or plain analysis facets?
A lot of the EV based mostly merchandise in market at present are for analysis use solely. These merchandise nonetheless have been permitted for medical functions. So, the EV based mostly liquid biopsy market was estimated utilizing these product revenues.
c) As you stated Azeet, there are numerous sequencer and PCR errors whereas sequencing, which makes it laborious to differentiate true mutants from these errors. How do you make it possible for is decreased?
We have now provide you with a technique generally known as clonal overlapping paired-end sequencing, by means of which we’re sequencing each strands of the DNA individually after which match the mutation overlaps. This manner solely the true mutations are left and all of the instrument mutations may be eliminated.
d) How do you count on the liquid biopsy strategies to enter the worldwide market. Which areas are adopting the strategies most shortly?
As per BIS analysis evaluation, North America is anticipated to dominate the worldwide liquid biopsy market in the course of the forecast interval 2022-2032. North America has a excessive adoption fee of liquid biopsy backed by a number of healthcare firms working within the area. The U.S. has the best implementation of PCR, NGS, and different applied sciences within the globe. However, Asia-Pacific is anticipated to witness the best compound annual progress fee (CAGR) of 15-25% in the course of the forecast interval 2022-2032. The expansion within the Asia-Pacific market is anticipated to be additional enhanced by different components equivalent to a rise in healthcare consciousness, a gradual financial system resulting in a better concentrate on genomic analysis, and the widespread adoption of genome sequencing as the usual of care.
to study extra about this subject? Watch the entire video beneath:
